Methods of treatment using CTLA4 mutant molecules
US7439230B2 · kind B2 · utility
18Cited by
27References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 3, 2004 |
| Grant date | Oct 21, 2008 |
| Priority date | — |
| Expiry date | Jun 30, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/51
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.